A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Pancreatic Cancer
Interventions
DRUG

MM-141

DRUG

Placebo

DRUG

Gemcitabine

DRUG

Nab-Paclitaxel

Trial Locations (66)

10032

Columbia University Medical Center, New York

Columbia University, New York

11733

North Shore Hematology Oncology Associates, PC, East Setauket

12351

Vivantes Klinikum Neukoelln, Berlin

14263

Roswell Park Cancer Inst, Buffalo

18015

St. Luke's University Health Network, Bethlehem

19111

Fox Chase Cancer Center, Philadelphia

28007

Hospital General Universitario Gregorio Marañon, Madrid

28050

Centro Integral Oncologico Clara Campal, Madrid

30265

Cancer Treatment Centers of America-Georgia, Newnan

33028

Memorial Regional Hospital, Pembroke Pines

37232

Vanderbilt-Ingram Cancer Ctr, Nashville

39008

Hospital Universitario Marques de Valdecilla, Santander

46010

Hospital Clinico Universitario de Valencia, Valencia

50937

Universitaetsklinikum Koeln, Cologne

60068

Oncology Specialists, S.C., Park Ridge

60611

Northwestern University, Chicago

60612

University of Illinois at Chicago, Chicago

66113

Caritasklinik St. Theresia, Saarbrücken

70503

Cancer Center of Acadiana Research Department, Lafayette

78234

Brooke Army Medical Center (BAMC), Fort Sam Houston

81675

Klinikum rechts der Isar - TUM, München

85234

Banner MD Anderson Cancer Ctr., Gilbert

90095

UCLA School of Medicine, Los Angeles

90277

Cancer Care Assoc Med Grp, Redondo Beach

92801

Pacific Cancer Medical Center, Inc., Anaheim

92835

St. Jude Heritage Healthcare, Fullerton

93105

Sansum Clinic, Santa Barbara

93454

Central Coast Med Onc Corp, Santa Maria

94115

UCSF Cancer Center, San Francisco

99216

Cancer Care Northwest, P.S., Spokane Valley

Unknown

Rocky Mountain Cancer Centers, Aurora

Baptist Health Med Gr Onc, LLC, Miami

Florida Cancer AffiliatesOcala, Ocala

Illinois Cancer Specialists, Chicago

Midwest Regional Medical Cntr, Zion

Nylen Cancer Center, Sioux City

Compr Cancer Centers of Nevada, Henderson

New York Oncology HematologyPC, Albany

Bassett Cancer Institute, Cooperstown

Mid Ohio Onco/ Zangmeister Ctr, Columbus

Tulsa Cancer Institute, PLLC, Tulsa

Allegheny Cancer Center, Pittsburgh

SCRI - Tennessee Oncology, Nashville

Texas Oncology-Austin Midtown, Austin

Texas Oncology P A Bedford, Bedford

Texas Oncology-Dallas P.H., Dallas

Texas Oncology-Paris, Paris

Texas Oncology-Plano East, Plano

Texas Oncology SA Medical Ctr, San Antonio

Texas Oncology-Tyler, Tyler

Virginia Cancer Specialists PC, Fairfax

Onc and Hem Asso of SW VA Inc, Salem

Northwest Cancer SpecialistsPC, Vancouver

Charite Universitaetsmd Berlin, Berlin

Uniwersyteckie Centrum Kliniczne, Gdansk

WSZ im. L. Rydygiera wToruniu, Torun

Hospital U de Fuenlabrada, Madrid

Royal Marsden Hospital, Sutton

01608

Reliant Medical Group, Inc., Worcester

T6G 1Z2

Cross Cancer Institute, Edmonton

08035

Hospital Universitari Vall d'Hebron, Barcelona

SE1 9RT

Guy's Hospital, London

W1G 6AD

Sarah Cannon Research Institute UK, London

M20 4BX

The Christie, Manchester

SM2 5PT

Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT02399137 - A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter